BC Platforms
BC Platforms provides an AI-driven genomic data analysis and management platform that transforms fragmented real-world data into decision-ready evidence for clinical, regulatory, payer, medical, and commercial decisions across the drug development lifecycle. The company's platform suite includes BC Unify (AI-driven end-to-end data mastering platform for ingesting, harmonizing, transforming, and enriching multi-modal…
Funding snapshot
About
BC Platforms provides an AI-driven genomic data analysis and management platform that transforms fragmented real-world data into decision-ready evidence for clinical, regulatory, payer, medical, and commercial decisions across the drug development lifecycle. The company's platform suite includes BC Unify (AI-driven end-to-end data mastering platform for ingesting, harmonizing, transforming, and enriching multi-modal data), BC Catalyst (a prompt-based precision medicine platform for AI-powered cohort building, biomarker discovery, and population health insights), BC Image (AI-driven platform automating image extraction, de-identification, and processing), BC Mosaic (trusted research environments for clinical, genomic, and multi-omics studies with regulatory-compliant audit trails), and BC Data (a global real-world data network for research and innovation). The platform leverages a unique AI-enabled federated architecture that helps reduce development timelines, shorten time to value, and enable personalized therapies, with data meeting EHDS and GDPR+ standards. BC Platforms serves life sciences companies (advancing discovery, development, regulatory approval, and market access) and healthcare organizations (anonymizing, monetizing, and safeguarding health data). The company has access to 187M+ patients, 20+ FDA/EMA submissions, over 90% of patients outside the US, and 150+ global data partners, and has signed a Strategic Collaboration Agreement with AWS to scale secure AI-powered research environments. BC Platforms differentiates itself through its 25+ years of experience, its federated analytics approach enabling patient-level data access without data movement, and its comprehensive multi-modal data capabilities spanning clinical, EMR, multi-omics, and imaging data. Founded in 1997 and headquartered in Zurich, Switzerland, BC Platforms has raised approximately $47.1 million in a Series D round backed by Boston Millennia Partners, Jolt Capital, Debiopharm, Tesi, IQVIA, Europa, BioMedPartners, and VP Venture Partners.
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Genomics > Sequencing Analysis,
Genomics > Genome Informatics > Sequence Analysis
Founders & team highlights
Serial Founder
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.